Verteporfin for recurrent EGFR-mutant glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests verteporfin (Visudyne), given through a vein, for recurrent glioblastoma that has an EGFR mutation or increased EGFR. It aims to shrink or slow the tumor after standard treatment has already been tried.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a grade 4 brain tumor (glioblastoma) that has come back or is worsening
- Your tumor testing shows an EGFR mutation or extra EGFR (amplified) from standard lab testing
- Your recent brain MRI shows true tumor progression (not just scar tissue from prior radiation)
- You already had brain radiation and it finished at least 90 days before starting this study
- You’re able to receive repeated IV treatments and are willing to get a central line/port (portacath)
- If you can get pregnant, you must have a negative pregnancy test and use reliable birth control during the study and for 8 weeks after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial tests whether using special MRI information to plan proton radiation, plus a drug called Avastin (bevacizumab), can help control recurrent glioblastoma (a fast-growing brain tumor) and improve outcomes. It mainly aims to treat tumor that has come back after prior standard radiation, using careful timing and imaging to target it safely.
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.
This trial tests two new drugs (ABBV-637 or ABBV-155) combined with ERAS-801 for people with recurrent glioblastoma (a type of brain cancer). It may help if your tumor has a specific genetic change (EGFR amplification) and you are having surgery to remove part of the tumor.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.